Technology | May 23, 2013

Syntermed Awarded 510(k) Clearance for Cardiac Imaging Decision Support System

Emory Toolbox 4.0 launches with new SmartReport.

Dr. Garcia with Emory (Cardiac) Toolbox software photo credit: Jack Kearse, Emory University

Dr. Garcia with Emory (Cardiac) Toolbox software photo credit: Jack Kearse, Emory University

 EmoryToolbox4_Syntermed

May 23, 2013 — Syntermed Inc. has been awarded 510(k) clearance for Emory Cardiac Toolbox version 4.0.

"One of the many things that makes Emory Toolbox 4.0 different is SmartReport, the first-ever, cloud-based nuclear cardiology reporting tool using decision support,” said Michael Lee, CEO, Syntermed Inc. The decision support system that powers SmartReport is called Syntermed IDS and will allow diagnosticians to perform faster, more accurate nuclear cardiology reports from single photon emission computed tomography (SPECT) and positron emission tomography (PET) heart scans.

The new Emory Toolbox 4.0 was totally rebuilt on a progressive .NET framework to maximize the computer and network technologies, but it still has the same familiar user-guide. Designed to increase lab workflow and efficiency, Toolbox 4.0 has a more intuitive user interface that supports a dynamic windows manager and a new 3-D display, and it offers simplified packaging whereby many of the existing tools are now a standard part of Toolbox 4.0.

“Syntermed Live, now in its sixth year of operation, gives physicians convenient 24/7-365 days a year remote access to studies and reports,” said Lee. “With the advent of Emory Toolbox 4.0 and our new SmartReport, powered by Syntermed IDS, reports are not only cloud-accessible but can now be fully integrated with electronic medical records (EMR) at the hospital enterprise level.”

The Emory Toolbox 4.0 is an Internet — Wi-Fi-based system and acquires the data from the electrocardiography (ECG)-gated myocardial perfusion SPECT studies, automatically reconstructing the data, then analyzing and converting it to quantitative parameters or factors of abnormality. This data is then submitted to an imaging decision support system that is continuously updated with the to reach an impression of the patient's heart status. The physician then sees the justification for the diagnosis and can make changes to the report. The entire process is designed to be faster, more efficient and user-friendly while providing a comprehensive report that is more easily accessible given today’s technology.

For more information: www.syntermed.com

Related Content

GE Healthcare Recalls Millennium Nuclear Medicine Systems
News | Nuclear Imaging | November 15, 2018
GE Healthcare announced it is recalling its Millennium Nuclear Medicine Systems due to an incident in which the the top...
Artificial Intelligence Predicts Alzheimer's Years Before Diagnosis
News | Neuro Imaging | November 14, 2018
Artificial intelligence (AI) technology improves the ability of brain imaging to predict Alzheimer’s disease, according...
Researchers Awarded 2018 Canon Medical Systems USA/RSNA Research Grants
News | Radiology Imaging | November 13, 2018
The Radiological Society of North America (RSNA) Research & Education (R&E) Foundation recently announced the...
Subtle Medical Showcases Artificial Intelligence for PET, MRI Scans at RSNA 2018
News | Artificial Intelligence | November 13, 2018
At the 2018 Radiological Society of North America annual meeting (RSNA 2018), Nov. 25-30 in Chicago, Subtle Medical...
University of Missouri Research Reactor First U.S. I-131 Supplier in 30 Years

MURR is the only supplier of I 131 in the United States and the first U.S. supplier since the 1980s. Image courtesy of University of Missouri

News | Radiopharmaceuticals and Tracers | November 13, 2018
The University of Missouri Research Reactor (MURR) recently shipped its first batch of Iodine-131 (I-131), a...
MEDraysintell Projects Increasing Mergers and Acquisitions in Nuclear Medicine
News | Nuclear Imaging | November 07, 2018
With the recent announcement by Novartis to acquire Endocyte , interest from the conventional pharmaceutical industry...
A PET/CT head and neck cancer scan.

A PET/CT head and neck cancer scan.

Feature | Nuclear Imaging | November 05, 2018 | By Sabyasachi Ghosh
“Experimental validation implemented in real-life situations and not theoretical claims exaggerating small advantages
PET Imaging Offers New Possibilities in Chronic Liver Disease Management

Hepatic 18F-FDG, 18F-FAC, and 18F-DFA accumulation are affected in a mouse model of autoimmune hepatitis. (A) Histochemical and immunohistochemical analyses of liver sections from vehicle- and ConA-treated mice. Scale bars represent 50 microns. Transverse PET/CT images (B) and quantification (C) of vehicle- and ConA-treated mice injected with 18F-FDG, 18F-FAC, and 18FDFA. Livers are outlined in a white dotted line. Quantification represents radiotracer accumulation in the liver normalized to a background organ. Image courtesy of Salas J.R., Chen B.Y., Wong A., et al.

News | PET Imaging | October 24, 2018
While liver biopsies are powerful and reliable, they are also invasive, painful, limited and subject to complications....
Siris Medical Releases PlanMD Decision Support Software
Technology | Treatment Planning | October 24, 2018
Siris Medical Inc. announced the release of its new artificial intelligence (AI) treatment decision-support system for...
CORAR Supports Medicare Diagnostic Radiopharmaceutical Payment Equity Act of 2018
News | Radiopharmaceuticals and Tracers | October 12, 2018
October 12, 2018 — The Council on Radionuclides and Radiopharmaceuticals Inc.